Chart-Typ:
Zeitraum:
| Lumen Technologies: Lumen and Meta Partner to Drive AI Network Expansion | Lumen's Private Connectivity Fabric enables long-term network capacity for Meta's AI DENVER, Oct. 21, 2024 /PRNewswire/ -- Lumen Technologies (NYSE: LUMN) and Meta are partnering to significantly... ► Artikel lesen |
| Vervierfacht in einem Monat: Spektakuläre Rallye: Ist Lumen Technologies die neue Super Micro? | © Foto: picture alliance / ASSOCIATED PRESS | Lindsey WassonNur wenige Unternehmen haben so einen kometenhaften Anstieg wie Lumen verzeichnet. Dank milliardenschwerer Aufträge hat sich die Aktie vervierfacht.... ► Artikel lesen |
| Lumen: Glasfaser-Spezialist sieht großes Potenzial in KI | MONROE, Louisiana (IT-Times) - Das Telekommunikationsunternehmen Lumen Technologies hat heute seine Ergebnisse für das zweite Quartal 2024 bekannt gegeben und einen rückläufigen Umsatz ausgewiesen.... ► Artikel lesen |
| RedHill Biopharma Ltd.: New Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 Mortality | Data, from a post hoc analysis of the randomized, placebo-controlled, double-blind phase 2/3 study of oral opaganib in COVID-19 pneumonia, showing a 62% reduction in mortality and a 21% improvement... ► Artikel lesen |
| RedHill Biopharma Ltd.: RedHill Biopharma Announces First Half 2024 Business Highlights | A transformed RedHill:
Numerous potential catalysts
Strengthened cash balance and control over our destiny following the Termination Agreement with Movantik Acquisition Co. and others: Executing on... ► Artikel lesen |
| RedHill Biopharma Ltd.: RedHill's Opaganib Granted Orphan Drug Designation by the FDA for Childhood Cancer, Neuroblastoma | Neuroblastoma is rare but is the most common infancy malignancy with a median age of diagnosis of 17 months. In the U.S., it accounts for up to around 10% of all childhood cancer cases and 15% of pediatric... ► Artikel lesen |
| Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Announces Submission of the TNX-102 SL New Drug Application (NDA) for Fibromyalgia to the U.S. Food and Drug Administration (FDA) | NDA based on two Phase 3 studies of TNX-102 SL in fibromyalgia with statistically significant results on the primary endpoint of reducing widespread pain; generally well tolerated TNX-102 SL is a... ► Artikel lesen |
| Tonix Pharmaceuticals Holding: The Rush for Non-Addictive Painkillers to Counter the Opioid Crisis Puts Two Companies Close to FDA Decisions | This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial support from Tonix. The two organizations... ► Artikel lesen |
| Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Announces Issuance of U.S. Patent Covering the Subcutaneous Delivery of FDA-Approved Zembrace SymTouch to Treat Migraines | New patent expected to provide market exclusivity into 2036 Zembrace® SymTouch® (sumatriptan succinate injection) 10mg is indicated for the acute treatment of migraine in adults CHATHAM, N.J., Sept.... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VSEE HEALTH INC finden Sie auf Wallstreet Online.
